Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases

• Main Authors: John R. van Sörnsen de Koste, Claire C. van Vliet, Famke L. Schneiders, Anna M.E. Bruynzeel, Berend J. Slotman, Miguel A. Palacios, Suresh Senan
• Format: Article
• Language: English
• Published: Elsevier 2021-10-01
• Series: Physics and Imaging in Radiation Oncology
• Subjects: SABR; Adrenal; Kidney; Organ at Risk; Renal dose constraints
• Online Access: http://www.sciencedirect.com/science/article/pii/S2405631621000518
• ISSN: 2405-6316

Stereotactic ablative radiotherapy (SABR) planning for adrenal metastases aims to minimize doses to the adjacent kidney. Renal dose constraints for SABR delivery are not well defined. In 20 patients who underwent MR-guided breath-hold SABR in five daily fractions of 8–10 Gy, ipsilateral renal volumes receiving ≥20 Gy best correlated with loss of renal volumes, with median renal volume reduction being 6% (range: 3%-11%, 10th-90th percentiles). Organ function did not deteriorate in 18 patients, who had post treatment renal function tests available. This suggests that the ipsilateral renal volume receiving 20 Gy can be used as partial organ dose constraint for SABR to targets in the upper abdomen.